GeoVax Labs, Inc. — 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. This is an annual report; it does not provide standalone fourth-quarter results. GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies using its MVA-VLP platform. It had no product sales; reported revenue came from grants and research collaborations.
Key financial metrics
| Metric | 2018 | 2017 |
|---|---|---|
| Grant and collaboration revenue | $963,203 | $1,075,270 |
| Research and development expense | $1,878,652 | $2,017,350 |
| General and administrative expense | $1,647,268 | $1,232,368 |
| Operating loss | $(2,562,717) | $(2,174,448) |
| Net loss | $(2,560,094) | $(2,170,162) |
| Net cash used in operating activities | $(1,543,026) | $(1,688,464) |
| Cash and cash equivalents at year-end | $259,701 | $312,727 |
| Working capital deficit at year-end | $(1,005,127) | $(363,218) |
| Total liabilities | $1,664,411 | $811,292 |
| Stockholders’ equity (deficiency) | $(1,022,347) | $(321,057) |
GeoVax reported an accumulated deficit of approximately $40.5 million. The filing does not present a meaningful commercial gross margin because the company had no product revenue.
Material changes and financing
- Revenue decreased about 10% year over year, while net loss increased about 18%. Research and development expense fell 6.9%; general and administrative expense rose about 34%, principally reflecting higher stock-based compensation. Total stock-based compensation increased to $469,723 from $57,224, including $314,419 for shares issued for nonemployee services.
- Operating cash use improved from 2017, but cash declined by $53,026 during 2018. Financing provided $1.49 million, including $1.19 million from Series E preferred stock and $300,000 from notes.
- Year-end notes payable totaled $300,000: $250,000 in short-term investor notes and a $50,000 five-year Georgia Research Alliance note bearing 5% interest. The investor notes were exchanged for Series G preferred stock in February 2019.
- Common shares outstanding increased from 106.7 million at year-end 2017 to 218.9 million at year-end 2018; 278.0 million were outstanding on March 22, 2019. The filing also lists 265.6 million shares reserved for options, warrants and preferred-stock conversions at year-end 2018. These securities and subsequent financings present substantial potential dilution.
Outlook, programs and risks
- Management estimated that cash, existing government grants, clinical-trial support and committed equity sources would fund planned operations into the third quarter of 2019. Additional capital would be needed thereafter; management planned to pursue grants, clinical-trial support and further securities offerings. There is no assurance financing would be available on acceptable terms.
- The auditor’s report raises substantial doubt about GeoVax’s ability to continue as a going concern, citing recurring operating losses and liabilities exceeding assets. The financial statements contain no adjustments for the outcome of that uncertainty.
- At year-end, $2.59 million of approved grant funds remained available for 2019 and 2020, but about $1.385 million was expected to reimburse third-party services. Management also disclosed $625,000 of vendor and subcontractor purchase commitments expected to be reimbursed under grants.
- The most advanced program was the clade B HIV vaccine. A 2018 booster study reported antibody titers increased more than 600-fold with a combined MVA and protein boost. A further HVTN Phase 1 trial was expected to begin enrollment in mid-2019, supported by NIAID. AGT separately planned a Phase 1 HIV immunotherapy trial in the second half of 2019.
- Other programs—including Zika, Ebola, Lassa fever, malaria, hepatitis B and cancer—were preclinical. Further development of several programs depended on additional funding or partnerships. The filing describes encouraging preclinical results, which do not establish human safety or efficacy.
- Key risks include dependence on external financing and government grants, clinical and regulatory uncertainty, reliance on third-party manufacturers and trial operators, lack of commercial manufacturing and sales capabilities, intense competition, and possible dilution from convertible securities and warrants. A proposed reverse stock split and possible Nasdaq listing were uncertain.
- Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2018. The auditor expressed no opinion on internal-control effectiveness.
Important facts for investors to verify
- Current cash runway, funding actually received after year-end, and the status and terms of any subsequent capital raises.
- Whether planned HIV trials and other development milestones began as expected, and the source and duration of trial funding.
- Current preferred-stock conversion terms, warrant coverage, anti-dilution provisions, and fully diluted share count.
- Whether remaining grant balances and the related purchase commitments are available and reimbursable as management anticipated.
- Any changes in going-concern disclosures, liabilities, or management salary and director-fee deferrals since the filing.